Biolegend, 741331, LEGENDplex™ SARS-CoV-2 Variants Neut. Ab Panel (6-plex) w/FP

SARS-CoV-2 continuously evolves as changes in the genetic code occur during replication of the genome. SARS-CoV-2 variants have been emerging and circulating around the world since the beginning of the COVID-19 pandemic, e.g. Alpha (B.1.1.7, first identified in United Kingdom), Beta (B.1.351, first identified in South Africa), Gamma (P.1, first identified in Brazil), Delta (B.1.617.2, first identified in India), etc. The Omicron variant (B.1.1.529) emerged in November 2021 in South Africa and it quickly spread throughout the world. LEGENDplex™ SARS-CoV-2 Variants Neut. Ab Panel (6-plex) is a multiplex beads-based competitive assay. Capture beads are pre-coated with six SARS-CoV-2 Spike protein Variants (Alpha, Beta, Gamma, Delta, Omicron, and Wild type S1 protein) conjugated onto fluorochrome-coded beads. Biotinylated ACE2 protein serving as the detection reagent will be added to all wells after adding the beads. Standard (anti-SARS-CoV-2 S Protein S1 antibody) or samples and the detection reagent will compete to bind to the capture beads, producing a competitive assay. Streptavidin-phycoerythrin (SA-PE) is subsequently added, which will bind to the biotinylated detection reagent, providing fluorescent signal intensities in proportion to the amount of bound analytes. The concentration of a neutralization antibody is determined using a standard curve generated in the same assay. Due to the nature of the assay, the standard curve will have the highest signal at the lowest standard neutralization antibody concentration and the signal will decrease as the standard neutralization antibody concentration increases.